Affiliations: [a] Maptimmune BV, The Hague, The Netherlands
| [b]
Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden
| [c]
Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden
| [d] QPS Austria GmbH, Neuropharmacology, Grambach, Austria
| [e]
Department of Neurodegenerative Disease, UCL Queen Square, Institute of Neurology, University College London, London, UK
| [f]
Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden
Correspondence:
[*]
Correspondence to: Thomas Vogels, Maptimmune, Wilde Ga-gel 30, 2498EP The Hague, The Netherlands. Tel.:+31 6 47219377; E-mail: t.vogels@maptimmune.com.
Abstract: Background:Alzheimer’s disease (AD) and other tauopathies are neurodegenerative disorders characterized by cellular accumulation of aggregated tau protein. Tau pathology within these disorders is accompanied by chronic neuroinflammation, such as activation of the classical complement pathway by complement initiation factor C1q. Additionally, about half of the AD cases present with inclusions composed of aggregated alpha-synuclein called Lewy bodies. Lewy bodies in disorders such as Parkinson’s disease and Lewy body dementia also frequently occur together with tau pathology. Objective:Immunotherapy is currently the most promising treatment strategy for tauopathies. However, the presence of multiple pathological processes within tauopathies makes it desirable to simultaneously target more than one disease pathway. Methods:Herein, we have developed three bispecific antibodies based on published antibody binding region sequences. One bispecific antibody binds to tau plus alpha-synuclein and two bispecific antibodies bind to tau plus C1q. Results:Affinity of the bispecific antibodies to their targets compared to their monospecific counterparts ranged from nearly identical to one order of magnitude lower. All bispecific antibodies retained binding to aggregated protein in patient-derived brain sections. The bispecific antibodies also retained their ability to inhibit aggregation of recombinant tau, regardless of whether the tau binding sites were in IgG or scFv format. Mono- and bispecific antibodies inhibited cellular seeding induced by AD-derived pathological tau with similar efficacy. Finally, both Tau-C1q bispecific antibodies completely inhibited the classical complement pathway. Conclusion:Bispecific antibodies that bind to multiple pathological targets may therefore present a promising approach to treat tauopathies and other neurodegenerative disorders.
